Avid Bioservices Inc (CDMO)

[atonewith PPHM]

Bio, Thank you for compiling this post. I noticed in the last quote by Joe Shan:
Quote:
Starting with breast cancer, we’ve now generated data from three separate clinical trials combining bavituximab with taxane chemotherapy. The most recent is from an investigator sponsored trial or IST by Dr. Alison Stopeck of the University of Arizona Cancer Center, in Tucson in which she previously reported an 85% response rate including a 15% complete response rate in patients with HER2-negative metastatic breast cancer.

Given these results in which approximately half of the patients were triple negative and extremely difficult to treat disease and the immune-stimulatory synergies that exist between bavituximab and taxane, breast cancer is high on our list of next indications. We look forward to the publication of final data in a manuscript form from this trial from Doctor Stopeck in the near future.
I wonder why he said, "previously reported". Have the numbers changed? Could they have changed for the better? Remember the statement from Dr. Stopeck, "prolonged immune responses"
Makes me go Hmmmm.
AtonewithPPHM